Investigating how aspirin affects immune responses in pregnant women at risk of preeclampsia
Investigating the Role of Neutrophils in Aspirin Treatment for Women at High Risk of Preeclampsia
This study is testing how low-dose aspirin might help pregnant women at risk of preeclampsia by looking at their immune responses to see if it makes a difference.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Queen Mary University of London Academic / other |
| Locations | 1 site (London) |
| Trial ID | NCT04974892 on ClinicalTrials.gov |
What this trial studies
This observational study aims to understand the immune mechanisms by which low-dose aspirin (LDA) may prevent preeclampsia in high-risk pregnant women. Participants will be categorized into two groups: those who respond to LDA and do not develop preeclampsia, and those who do not respond and develop the condition. Blood tests will be conducted to assess the immune profile of these participants, focusing on the role of neutrophils in the treatment's effectiveness. The study is conducted at Barts Health NHS Trust and involves women aged 18 to 60 with singleton pregnancies who are taking LDA as part of their routine care.
Who should consider this trial
Good fit: Ideal candidates are pregnant women aged 18-60 with a singleton pregnancy who are taking low-dose aspirin as standard care.
Not a fit: Patients who are unwilling or unable to give consent or cannot understand written English may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and treatment options for women at high risk of developing preeclampsia.
How similar studies have performed: While the specific approach of this study is novel, previous studies have indicated the importance of neutrophils in mediating anti-inflammatory responses in preeclampsia.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria * Age 18-60 years * Singleton pregnancy * Live fetus at 11-13 weeks of gestation * Informed, written consent * Upper age of 60 years * Patient taking low dose aspirin as standard of care Exclusion criteria * Unwilling or unable to give consent * Participants who are unable to understand written English
Where this trial is running
London
- Barts Health NHS Trust, The Royal London Hospital — London, United Kingdom (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.